Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

Table 4 Uni- and multivariate Cox regression models for PFS (N = 86)

	Univariate Cox regression model		Multivariate Cox regression model^a		Multivariate Cox regression model^b
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
γ-H2AX^pos/pATM^pos
Positive vs other	2.14 (1.30–3.53)	0.003	2.09 (1.27–3.45)	0.004	1.87 (1.04–3.39)	0.038
TAZ^pos/WNT^mut
Positive vs other	2.27 (1.27–4.05)	0.006	2.21 (1.23–3.97)	0.008	2.73 (1.41–5.29)	0.003
ECOG-PS
1–2 vs 0	1.23 (0.77–1.97)	0.391			1.20 (0.73–1.95)	0.471
Stage
Met vs loc adv	1.12 (0.69–1.80)	0.647			0.89 (0.46–1.73)	0.737
Localization
Stomach vs EOJ	0.67 (0.27–1.69)	0.398			1.54 (0.53–4.42)	0.424
Number of metastatic sites
2–3 vs 1	1.57 (0.93–2.65)	0.089			1.33 (0.70–2.50)	0.379
Peritoneal metastasis
Yes vs No	0.67 (0.42–1.07)	0.097			0.72 (0.41–1.27)	0.261
Taxanes
Yes vs No	0.93 (0.58–1.51)	0.784			0.79 (0.45–1.40)	0.429